Dr. Reddy's Laboratories Ltd

The investor presentation for Dr. Reddy's Laboratories Limited's Q2FY27 results, dated October 23, 2026, outlines financial and operational highlights. Reported revenues were ₹8,671 crore, showing a 1.5% YoY decline due to lower lenalidomide sales but a 7% QoQ increase. EBITDA reached ₹1,783 crore with a 20.6% margin, up 24% YoY and 77% QoQ. PBT and PAT also showed significant growth. Strategic initiatives included partnerships for dengue vaccine QDENGA, expanded collaborations with Gilead Sciences, and approvals for biosimilars like rituximab and nivolumab. The CDMO business under Aurigene Pharmaceutical Services surpassed $100 million in annualized revenue. However, the presentation notes challenges such as API-related issues, regulatory inspections with observations, and the impact of lower API volumes on PSAI performance. The company emphasized growth in core businesses, innovation in peptides and biosimilars, and operational efficiencies. The document also includes non-GAAP financial measures for analysis.

The document highlights both growth in key areas and challenges such as API-related issues and regulatory inspections.